Gastric electrical stimulation with Enterra therapy improves symptoms of idiopathic gastroparesis
R W McCallum, I Sarosiek, H P Parkman, W Snape, F Brody, J Wo, T Nowak, R W McCallum, I Sarosiek, H P Parkman, W Snape, F Brody, J Wo, T Nowak
Abstract
Background: Gastric electrical stimulation (GES) is a therapeutic option for intractable symptoms of gastroparesis (GP). Idiopathic GP (ID-GP) represents a subset of GP.
Aims: A prospective, multicenter, double-blinded, randomized, crossover study to evaluate the safety and efficacy of Enterra GES in the treatment of chronic vomiting in ID-GP.
Methods: Thirty-two ID-GP subjects (mean age 39; 81% F, mean 7.7 years of GP) were implanted with GES. The stimulator was turned ON for 1½ months followed by double-blind randomization to consecutive 3-month crossover periods with the device either ON or OFF. ON stimulation was followed in unblinded fashion for another 4.5 months. Twenty-five subjects completed the crossover phase and 21 finished 1 year of follow-up.
Key results: During the unblinded ON period, there was a reduction in weekly vomiting frequency (WVF) from baseline (61.2%, P < 0.001). There was a non-significant reduction in WVF between ON vs OFF periods (the primary outcome) with median reduction of 17% (P > 0.10). Seventy-five percent of patients preferred the ON vs OFF period (P = 0.021). At 1 year, WVF remained decreased (median reduction = 87%, P < 0.001), accompanied by improvements in GP symptoms, gastric emptying and days of hospitalization (P < 0.05).
Conclusions & inferences: (i) In this prospective study of Enterra GES for ID-GP, there was a reduction in vomiting during the initial ON period; (ii) The double-blind 3-month periods showed a non-significant reduction in vomiting in the ON vs OFF period, the primary outcome variable; (iii) At 12 months with ON stimulation, there was a sustained decrease in vomiting and days of hospitalizations.
Keywords: gastric stimulation; gastroparesis; idiopathic gastroparesis; nausea; vomiting.
© 2013 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Figures
References
- Soykan I, Sivri B, Sarosiek I, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig Dis Sci. 1998;43:2398–404.
- Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology. 2004;127:2589–91.
- Hasler WL. Gastroparesis: symptoms, evaluation, and treatment. Gastroenterol Clin N Am. 2007;36:619–47.
- Kong M-F, Horowitz M, Jones KL, et al. Natural history of Diabetic Gastroparesis. Diabetes Care. 1999;22:503–7.
- Hasler WL. Gastroparesis-current concepts and considerations. Medscape J Med. 2008;10:16.
- McCallum RW, Soffer E, Pasricha J, et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol Motil. 2006;18:263–83.
- Reddymasu S, McCallum RW. Pharmacotherapy of gastroparesis. Expert Opin Pharmacother. 2009;10:1–16.
- Arts J, van Gool S, Caenepeel P, Verbeke K, Janssens J, Tack J. Influence of intrapyloric botulinum toxin injection on gastric emptying and meal-related symptoms in gastroparesis patients. Aliment Pharmacol Ther. 2006;24:661–7.
- Bromer MQ, Friedenberg F, Miller LS, Fisher RS, Swartz K, Parkman HP. Endoscopic pyloric injection of botulinum toxin A for the treatment of refractory gastroparesis. Gastrointest Endosc. 2005;61:833–9.
- US Food and Drug Administration. p. 47. H990014—EnterraTM therapy system (formerly named gastric electrical stimulation (GES) system). Available at: . Accessed March 31, 2000.
- McCallum RW, Lin Z, Forster J, Roeser K, Hou Q, Sarosiek I. Gastric electrical stimulation improves outcome of patients with gastroparesis for up to 10 years. Clin Gastroenterol Hepatol. 2011;9:314–9.
- McCallum R, Lin Z, Wetzel P, Sarosiek I, Forster J. Clinical response to gastric electrical stimulation in patients with postsurgical gastroparesis. Clin Gastroenterol Hepatol. 2005;3:49–54.
- Abell T, McCallum RW, Hocking M, et al. Gastric electrical stimulation for medical refractory gastroparesis. Gastroenterology. 2003;125:421–8.
- Abell T, Lou J, Tabbaa M, et al. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. J Parenter Enteral Nutr. 2003;27:277–81.
- Lin Z, Sarosiek I, Forster J, McCallum RW. Symptom responses, long-term outcomes and adverse events beyond 3 years of high-frequency gastric electrical stimulation for gastroparesis. Neurogastroenterol Motil. 2006;18:18–27.
- McCallum RW, Pasricha PJ. Gastroparesis and gastric electrical stimulation: a useful option for gastroparesis. AGA Perspectives. 2006;2:5.
- Soffer E, Abell T, Lin Z, et al. Review article: gastric electrical stimulation for gastroparesis – physiological foundations, technical aspects and clinical implications. Aliment Pharmacol Ther. 2009;30:681–94.
- Namin F, Lin Z, Sarosiek I, McCallum RW. Gastric electrical stimulation: who are the best candidates and what are the results. Pract Gastroenterol. 2005;8:28–47.
- House A, Champion MC, Chamberlain M. National survey of radionuclide gastric emptying studies. Can J Gastroenterol. 1997;11:317–21.
- Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol. 2000;95:1456–62.
- Forster J, Sarosiek I, Delcore R, et al. Gastric pacing is a new surgical treatment for gastroparesis. Am J Surg. 2001;182:676–81.
- Ware JE, Kosinski M. QualityMetric. Lincoln, RI: QualityMetric Incorporated; 2001. SF-36 physical & mental health summary scales: a manual for users of version 1. In: 2nd edn.
- Cutts TF, Luo J, Starkebaum W, et al. Is gastric electrical stimulation superior to standard pharmacological therapy in improving GI symptoms, healthcare resources, and long-term health care benefits? Neurogastroenterol Motil. 2005;17:35–43.
- Lin Z, McElhinney C, Sarosiek I, Forster J, McCallum RW. Chronic gastric electrical stimulation for gastroparesis reduces the use of prokinetic and/or antiemetic medications and the need for hospitalization. Dig Dis Sci. 2005;50:1328–34.
- McCallum RW, Snape W, Brody F, Wo J, Parkman HP. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol. 2010;8:947–54.
- Bityutskiy L, Soykan I, McCAllum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis, clinical characteristics and long-term outcome. Am J Gastroenterol. 1997;92:1501–4.
- Pande H, Lacy BE, Crowell MD. Inflammatory causes of gastroparesis: report of five cases. Dig Dis Sci. 2002;47:2664–8.
- Revicki DA, Rentz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther. 2003;18:141–50.
- Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737–49.
Source: PubMed